Avanos Medical, Inc.
AVNS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $177,800 | $175,000 | $167,500 | $179,600 |
| % Growth | 1.6% | 4.5% | -6.7% | – |
| Cost of Goods Sold | $96,700 | $82,900 | $77,700 | $80,300 |
| Gross Profit | $81,100 | $92,100 | $89,800 | $99,300 |
| % Margin | 45.6% | 52.6% | 53.6% | 55.3% |
| R&D Expenses | $5,800 | $5,800 | $5,400 | $5,700 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $62,200 | $79,000 | $77,100 | $81,100 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $68,000 | $84,800 | $82,500 | $86,800 |
| Operating Income | $13,100 | $7,300 | $7,300 | $12,500 |
| % Margin | 7.4% | 4.2% | 4.4% | 7% |
| Other Income/Exp. Net | -$14,300 | -$83,200 | $2,400 | -$433,000 |
| Pre-Tax Income | -$1,200 | -$75,900 | $9,700 | -$420,500 |
| Tax Expense | $200 | $900 | $3,100 | -$23,500 |
| Net Income | -$1,400 | -$76,800 | $6,600 | -$397,300 |
| % Margin | -0.8% | -43.9% | 3.9% | -221.2% |
| EPS | -0.03 | -1.66 | 0.14 | -8.64 |
| % Growth | 98.2% | -1,285.7% | 101.6% | – |
| EPS Diluted | -0.03 | -1.66 | 0.14 | -8.64 |
| Weighted Avg Shares Out | 46,400 | 46,100 | 46,100 | 46,000 |
| Weighted Avg Shares Out Dil | 46,400 | 46,800 | 46,800 | 46,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $500 | $600 | $1,500 | $800 |
| Interest Expense | $1,800 | $2,000 | $2,100 | $2,800 |
| Depreciation & Amortization | $9,400 | $10,000 | $9,600 | $11,100 |
| EBITDA | $10,000 | -$63,900 | $21,400 | -$406,600 |
| % Margin | 5.6% | -36.5% | 12.8% | -226.4% |